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Abstract
Background: Only 5–10 % of breast cancer cases is linked to germline mutations in the BRCA-1 gene and occurs
early in life. Conversely, sporadic breast tumors, which represent 90-95 % of breast malignancies, have lower BRCA-1
expression, but not mutated BRCA-1 gene, and tend to occur later in life in combination with other genetic
alterations and/or environmental exposures. The latter may include environmental and dietary factors that activate
the aromatic hydrocarbon receptor (AhR). Therefore, understanding if changes in expression and/or activation of
the AhR are associated with somatic inactivation of the BRCA-1 gene may provide clues for breast cancer therapy.
Methods: We evaluated Brca-1 CpG promoter methylation and expression in mammary tumors induced in
Sprague–Dawley rats with the AhR agonist and mammary carcinogen 7,12-dimethyl-benzo(a)anthracene (DMBA).
Also, we tested in human estrogen receptor (ER)α-negative sporadic UACC-3199 and ERα-positive MCF-7 breast
cancer cells carrying respectively, hyper- and hypomethylated BRCA-1 gene, if the treatment with the AhR
antagonist α-naphthoflavone (αNF) modulated BRCA-1 and ERα expression. Finally, we examined the association
between expression of AhR and BRCA-1 promoter CpG methylation in human triple-negative (TNBC), luminal-A
(LUM-A), LUM-B, and epidermal growth factor receptor-2 (HER-2)-positive breast tumor samples.
Results: Mammary tumors induced with DMBA had reduced BRCA-1 and ERα expression; higher Brca-1 promoter
CpG methylation; increased expression of Ahr and its downstream target Cyp1b1; and higher proliferation markers
Ccnd1 (cyclin D1) and Cdk4. In human UACC-3199 cells, low BRCA-1 was paralleled by constitutive high AhR
expression; the treatment with αNF rescued BRCA-1 and ERα, while enhancing preferential expression of CYP1A1
compared to CYP1B1. Conversely, in MCF-7 cells, αNF antagonized estradiol-dependent activation of BRCA-1
without effects on expression of ERα. TNBC exhibited increased basal AhR and BRCA-1 promoter CpG methylation
compared to LUM-A, LUM-B, and HER-2-positive breast tumors.
Conclusions: Constitutive AhR expression coupled to BRCA-1 promoter CpG hypermethylation may be predictive
markers of ERα-negative breast tumor development. Regimens based on selected AhR modulators (SAhRMs) may
be useful for therapy against ERα-negative tumors, and possibly, TNBC with increased AhR and hypermethylated
BRCA-1 gene.
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Background
Germline mutations in the BRCA-1 gene confer a high
probability of developing breast (~65 %) and ovarian
(~40 %) tumors [1–6]. Breast tumors lacking BRCA-1
tend to be triple-negative (TNBC) basal-like character-
ized by reduced expression of estrogen receptor-α (ERα),
progesterone receptor (PR), and epidermal growth factor
receptor-2 (HER-2) [7]. However, in spite of the high
penetrance, BRCA-1 mutations explain only a small per-
centage (5-10 %) of breast tumor cases [8]. Sporadic breast
tumors do not harbor somatic mutations in BRCA-1 but
express low or undetectable BRCA-1 [9–13].
A mechanism that may contribute to reducing expres-
sion of BRCA-1 in sporadic breast cancers is epigenetic
inactivation [14], which refers to modifications in DNA
CpG methylation, histone posttranslational modifica-
tions, chromatin remodeling factors, and non-coding
RNAs [15]. Various degrees of BRCA-1 promoter CpG
methylation have been observed in sporadic breast tu-
mors [16] ranging from ~10 to 85 % depending on
tumor type (ductal invasive > lobulo-alveolar) [17–23].
Causes contributing to BRCA-1 silencing remain largely
unknown. Sporadic breast tumors tend to display char-
acteristics of BRCA-1 mutation cancers (i.e. BRCAness)
[24]. These include a high degree of correlation (~75 %)
between hypermethylation of the BRCA-1 and ERα
(ESR1) genes, and reduced expression of BRCA-1 and
ERα [25–29]. Therefore, unraveling the cellular pro-
cesses that place CpG methylation marks on the BRCA-
1 gene [30] may assist with the formulation of therapies
against loss of BRCA-1 expression in BRCA-1 mutation
carriers [31] and non-BRCA-1 mutation patients [32].
Agonists of the aromatic hydrocarbon receptor (AhR)
are ubiquitous in the environment and include dietary
compounds, metabolites of fatty acids, industrial xenobi-
otics, and skin photoproducts generated through exposure
to ultraviolet radiation [33]. Importantly, the expression of
the AhR and downstream gene targets such as CYP1B1
are increased in human and rodent mammary tumors [34,
35]. Consequently, the use of selective modulators of the
AhR (SAhRMs) has been proposed in breast cancer ther-
apy [36].
Previously, we reported that AhR agonists repressed
estradiol (E2)-dependent BRCA-1 transcription in hu-
man breast cancer cells [37–41]. This repressive effect
was linked to increased recruitment to the BRCA-1 pro-
moter of the activated AhR and other factors associated
with the epigenetic machinery [42] including DNA
methyl-transferase-1, (DNMT-1), DNMT-3a and -3b;
methyl-binding domain protein-2 (MBD2); and place-
ment of histone-3 trimethylation marks on lysine-9
(H3K9me3) [43]. In AhR-activated human breast cancer
cells, the pattern of BRCA-1 promoter CpG methylation
[44] coincided with the one detected in human sporadic
breast tumors [45, 46]. Recently, using a rodent model
we found that gestational activation of the AhR in-
creased CpG methylation of the Brca-1 gene while redu-
cing BRCA-1 expression in mammary tissue of female
offspring. The latter changes were overridden by gesta-
tional pretreatment with an AhR antagonist [47]. These
cumulative data draw attention to the fact alterations of
AhR expression and activity may play a role in the eti-
ology of breast tumorigenesis. Nevertheless, the connec-
tion between higher AhR expression and/or activation
and BRCA-1 promoter hypermethylation in breast tu-
mors has not been investigated.
This study reports that rat mammary tumors induced
with the AhR-agonist 7,12-dimethyl-benzo(a)anthracene
(DMBA) [48] had augmented CpG methylation of the
Brca-1 gene; higher expression of Ahr, Cyp1b, and prolif-
eration markers (Cdk4, Ccnd1); and diminished expres-
sion of BRCA-1 and ERα. In cell culture experiments,
the treatment with α-naphthoflavone (αNF), a prototype
SAhRM, exerted cell line-specific effects: in ERα-
negative human UACC-3199 sporadic breast cancer cell
line, it rescued BRCA-1 and ERα expression, while indu-
cing CYP1A1; in ERα-positive MCF-7 breast cancer cells,
αNF antagonized E2-dependent stimulation of BRCA-1
without affecting ERα expression. Finally, we document
that human TNBC had higher AhR expression and
BRCA-1 promoter CpG methylation compared to human
luminal-A (LUM-A), LUM-B, and HER-2-positive breast
tumors. We conclude that constitutive high expres-
sion of AhR associated with BRCA-1 gene hyperme-
thylation may be prognostic markers of ERα-negative
breast tumor development. Therapies based on
SAhRMs may hold promise for rescue of BRCA-1
and ERα expression in ERα-negative breast cancers.
Methods
Animal experiments
Weaned female Sprague–Dawley rats and AIN-76A diet
were purchased from Harlan Laboratories (Houston,
Texas). At day 50 of age, 8 animals/group (n = 8) were
assigned to either a sesame oil vehicle control group, or
a treatment group receiving 10 mg/animal of DMBA
(Sigma-Aldrich, St. Louis, MO) by oral gavage [48]. Ani-
mals were palpated weekly, and mammary tumors were
collected when they reached a diameter of 1 cm. Ani-
mals were sacrificed according to a protocol approved
by the IACUC Committee of the University of Arizona.
Mammary gland tissues and tumors were collected and
stored frozen until further analysis.
Cell culture experiments
Human MCF-7 and UACC-3199 breast cancer cells were
obtained from the American Type Culture Collection
(Manassas, VA). MCF-7 and UACC-3199 cells were
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maintained, respectively, in Dulbecco’s Modified Eagles
Media (DMEM) or RPMI 1640 media (Mediatech,
Manassas, VA) supplemented with 10 % fetal calf serum
(FCS) (Hyclone Laboratories, Logan, UT). αNF and E2
for cell culture experiments were obtained from Sigma-
Aldrich (St. Louis, MO). For experiments with αNF
and E2, cells were plated in 6-well plates at a density of
5 × 105/cells/well. Then, after 24 h cells were cultured
for an additional 72 h in phenol-red free DMEM
(MCF-7) or RPMI (UACC-3199) supplemented with
10 % charcoal-stripped FCS plus 2 μM αNF in the
presence or absence of 10 nM E2 [42]. For Western
blotting, at the end of the incubation period, cells were
washed with ice-cold phosphate buffer saline (PBS)
and scraped with cold lysis buffer containing protease
inhibitor. For mRNA studies, at the end of the incuba-
tion period, cells were washed with ice-cold PBS. Ex-
traction of RNA was carried out using Triazol Reagent
(ThermoFisher Scientific, Grand Island, NY). Cell ex-
tracts and RNA samples were stored frozen at -20 °C
until further use.
Breast tumor collection
Human normal and breast tumor tissue sections were
obtained de-identified from the University of Arizona
Cancer Center Tissue Acquisition and Cellular/Molecu-
lar Analysis Shared Resource with the approval from the
Institutional Review Board of the University of Arizona,
Approval Form#F309. No patient-level correlations be-
tween gene activation information and individual patient-
data were performed, according to U.S. Department of
Human Health Services and Federal Drug Administration
regulations, and in compliance with the World Medical
Association Declaration of Helsinki (http://www.wma.net/
en/30publications/10policies/b3/index.html). The pres-
ence of tumor in each sample was confirmed by a staff
pathologist and classified according to the following cri-
teria: (i) TNBC: basal-like, and cytokeratin-, ERα-, PR-,
HER-2-, and epidermal growth factor-negative; (ii) HER-
2-positive: HER-2-positive and ERα-negative; (iii) LUM-A:
ERα-positive and/or PR-positive, and HER-2-negative; and
(iv) LUM-B: ERα-positive and/or PR-positive, and HER-2-
positive. As controls, we also obtained sections of non-
tumor tissue from the region surrounding TNBC and
LUM-B tumors.
Western blot analyses
Western blot analyses were performed as previously de-
scribed [47]. Immunoblotting was carried out with anti-
bodies against human BRCA-1 (Cat. #9010); glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (Cat. #2118)
(Cell Signaling Technology, Beverly, MA); rat BRCA-1
(Cat. #sc-642); AhR (Cat. #sc-5579); and ERα (Cat. #sc-542)
(Santa Cruz Biotechnology, Dallas, TX). Immunocomplexes
were detected using enhanced chemiluminescence (GE
Healthcare Life Sciences, Little Chalfont, UK). The GAPDH
protein was used as an internal control for normalization of
protein expression.
Promoter CpG methylation
Measurements of rat Brca-1 promoter CpG methylation
were carried out as described previously [47]. Briefly,
genomic DNA was isolated from ~30 mg of mammary
tissue using the DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA). Then, DNA (1 μg) was subjected to bisul-
fite modification using the CpGenome DNA Modification
Kit (Millipore, Billerica, MA). In preliminary experiments,
we verified that the number of cycles for semiquantitative
amplification of the rat Brca-1 promoter fragment with
unmethylated (U)- and methylated (M)-specific primers
was performed in the linear range (Fig. 2a). Then, the
bisulfite-modified genomic DNA obtained from 8 ani-
mals/group (n = 8) was analyzed by PCR as follows: 1 cycle
at 95 °C for 5 min; 37 cycles at 95 °C for 45 s, 55 °C (U)
and 59 °C (M) for 45 s, and 72 °C for 1 min; and 1 cycle at
72 °C for 5 min. Briefly, reactions were carried out at a
final volume of 25 μL consisting of the following master
mix: bisulfite-modified DNA, JumpStart Taq DNA poly-
merase, 1X PCR buffer, 2.0 mM MgCl2, 200 mM dNTPs,
1 μL each of forward and reverse primers. The PCR amp-
lification products were separated on 2 % agarose gels and
visualized using ethidium bromide staining. The rat Brca-
1 amplicon was of the expected size (142 bp) and its au-
thenticity to the rat Brca-1 gene [49] was confirmed by
direct sequencing. The rat Brca-1 primers synthesized by
Sigma-Aldrich (St. Louis, MO) were: U-sense: 5’-GTGAG
AAGGTTTTTGTTGTATT-3’, and U-antisense: 5’-CCAA
TTCCAACATACATTACA-3’; M-sense: 5’-GCGAGAA
GGTTTTTGTTGTATC-3’, and M-antisense: 5’-ACCAA
TTCCAACATACATTACG-3’.
Quantitative (qPCR) analysis of human BRCA-1 pro-
moter CpG methylation in control breast tissue and
breast tumors was performed in bisulfonated genomic
DNA using the following primers synthesized by Sigma-
Aldrich (St. Louis, MO): U-sense: 5'-TTGGTTTTTG
TGGTAATGGAAAAGTGT-3', and U-antisense: 5'-CAA
AAAATCTCAACAAACTCACACCA-3’; M-sense: 5’-T
GGTAACGGAAAAGCG-3’, and M-antisense 5’-ATCT
CAACGAACTCACGC-3’. The qPCR was carried out in
a volume of 10 μL consisting of the following master
mix: 5 μL of SYBER Green mix (Life Technologies,
Grand Island, NY), 1 μL each of forward and reverse
primers, 2 μL nuclease-free water, and 1 μL of bisulfo-
nated genomic DNA.
mRNA analyses
Sections of normal mammary gland and mammary
tumor tissues from 8 animals/group (n = 8) were
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homogenized (1 mL/40 mg of tissue) of QIAzol Reagent
(Invitrogen, Carlsbad, CA). Total RNA was purified
using RNeasy Lipid Tissue Mini Kit as per manufac-
turer’s instructions (Qiagen, Valencia, CA) [47]. Concen-
trations and quality of RNA were verified using the
Nanodrop1000 Spectrophotometer (Thermo Scientific,
Wilmington, DE). Equal amounts of total RNA (500 ng)
were transcribed into cDNA using ISCRIPT supermix
kit (Bio-Rad Laboratories, Hercules, CA). Next, cDNA
aliquots were analyzed by qPCR using the SYBR Green
PCR Reagents kit (Life Technologies, Grand Island, NY).
Briefly, reactions were run at a final volume of 25 μL
consisting of the following master mix: 12.5 μL of SYBR
Green mix, 1 μL each of forward and reverse primers,
9.5 μL nuclease-free water, and 1 μL cDNA. Amplification
of Gapdh mRNA was used for normalization of transcript







3’; antisense: 5-AGGTGTTGGCAGTGGTGGCAT-3’; Cdk4,
sense: 5’-TGCAACGCCTGTGGATATGT-3’, antisense: 5’-C
AGATTCCTCCATCTCCGGC-3’; Ccnd1 (cyclin D1), sense:
5’-CTGGCCATGAACTACCTGGA-3’, antisense: 5’-GTCAC
ACTTGATCACTCTGG-3’; Gapdh, sense: 5’-TGGTGAA
GGTCGGTGTGAAC-3’; antisense: 5’-AGGGGTCGTTGAT
GGCAACA-3’. For cell culture experiments with human
UACC-3199 breast cancer cells, the primer (Sigma-Aldrich,
St. Louis, MO) sequences were: BRCA-1, sense: 5′-AGCT
CGCTGAGACTTCCTGGA-3′, antisense: 5′-CAATTCAAT
GTAGACAGACGT-3′; GAPDH, sense: 5’-ACCCACTCC
TCCACCTTT-3’, antisense: 5’-CTCTTGTGCTCTTGCTGG




AhR measurements in human breast tissues and tumors,




Densitometry after Western blotting and CpG methyla-
tion analyses were performed using Kodak ID Image
Analysis Software (Eastman Kodak Company, Rochester,
NY). Statistical analyses were performed using Prism 5.0
(GraphPad Software Inc., La Jolla, CA) [47]. Data were
analyzed by 1-way ANOVA. Post-hoc multiple compari-
sons among all means were conducted using Tukey’s Test
after main effects and interactions were found to be sig-
nificant at P ≤ 0.05. Data were presented as means ± SEM
and statistical differences highlighted with different letters
or asterisks.
Results
BRCA-1 expression in mammary tumors
Previous studies documented a high degree (~75 %) of
correlation between loss of BRCA-1 and reduced ERα
expression in human breast tumors [27, 28]. Results of
BRCA-1 and ERα protein expression in control mam-
mary tissue, and in adjacent normal mammary tissues
and tumors obtained from animals treated with DMBA
are presented in Fig. 1. Compared to control mammary
gland, BRCA-1 expression (Fig. 1a) was reduced by an aver-
age 50 % in peritumoral mammary tissue (Fig. 1b). BRCA-1
protein levels were reduced by an additional ~40 % in
DMBA-induced mammary tumors. Similarly, we found
that compared to control mammary tissue, ERα levels
were reduced by an average 40 % and 70 % respectively,
in DMBA-treated but apparently normal mammary
gland, and mammary tumors.
Fig. 1 Expression of BRCA-1 and ERα are reduced in DMBA-induced
mammary adjacent tissues and tumors. a Bands are representative
immunocomplexes for BRCA-1 and ERα in control mammary gland,
and mammary adjacent tissue and tumors obtained from four
(1 through 4) DMBA-treated rats; b Bars represent means ± SEM
of quantitation (fold change of control) of BRCA-1 and ERα protein
corrected for GAPDH protein as internal standard in mammary adjacent
tissues and tumors from 8 animals/group (n = 8). Different letters
represent statistical differences (P < 0.05)
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Brca-1 promoter CpG methylation in mammary tumors
To examine if the reduction in BRCA-1 expression in
DMBA-treated animals was related to changes in Brca-1
promoter CpG methylation status, we extracted genomic
DNA from control mammary gland, and adjacent mam-
mary tissues and tumors from DMBA-treated animals.
In control experiments, we ascertained that rat bisulfo-
nated genomic DNA obtained from control mammary
tissue was amplified in the linear range with U- and M-
specific Brca-1 oligonucleotides, and Brca-1 amplicons
were of the expected size (142 bp) (Fig. 2a). Turning to
changes in Brca-1 promoter CpG methylation (Fig. 2b),
we found that compared to control, the adjacent mam-
mary gland isolated from DMBA-treated animals had an
average 1.9-fold increase in Brca-1 promoter CpG
methylation (Fig. 2c), which was increased on average an
additional ~1.0-fold in DMBA-induced tumors (Fig. 2c).
These data suggested that the Brca-1 gene was a target
for repression via CpG methylation in mammary tissue
of animals treated with the AhR agonist and mammary
carcinogen, DMBA.
AhR expression and activation in mammary tumors
Focusing on measurements of Ahr expression and acti-
vation, we first examined changes in Ahr in mammary
tissue of control animals, and peritumoral and tumor tis-
sues obtained from DMBA treated animals (Fig. 3).
Compared to control, levels of Ahr were increased ~2.7-
fold in peritumoral tissues; Ahr expression was increased
an additional ~4.5-fold in DMBA-induced mammary tu-
mors. In human breast cancer cell lines, higher CYP1B1
expression over CYP1A1 has been related to higher AhR
expression and ERα-negative status [50]. Therefore, we
measured changes in expression of Cyp1a1 and Cyp1b1
as controls for AhR pathway activation. Basal Cyp1a1
was reduced by 30 and 70 % respectively in adjacent
mammary gland and mammary tumors (Fig. 4a). Con-
versely, Cyp1b1 levels were markedly increased, on
average ~5.0 and 14.0-fold of control, respectively in
peritumoral tissue and mammary tumors (Fig. 4b).
These data indicated that constitutive overexpression
of the Ahr in rat mammary tumors was coupled with
differential regulation on the Cyp1a1 (repression) and
Cyp1b1 (activation) target genes.
Proliferation markers in mammary tumors
Previous investigations documented that increased ex-
pression and activation of the AhR may be associated
with mitogenic responses [51, 52], and increased Cdk4
Fig. 2 Brca-1 promoter methylation is increased in DMBA-induced
rat mammary adjacent tissues and tumors. a Cycle number and
no-template control (NTC) for amplification of rat Brca-1 promoter
with U- and M-specific primers. MW, molecular weight markers; b
Methylation status of Brca-1 promoter in control mammary gland,
and in adjacent mammary tissues and tumors of four representative
(1-4) animals; C) Quantitation from genomic DNA of Brca-1 promoter
methylation status (M/U ratio) compared to control from 8 animals/
group (n = 8). Means ± SEM without a common letter differ (P < 0.05)
Fig. 3 Expression of Ahr is increased in DMBA-induced rat mammary
adjacent tissues and tumors. Bars represent means ± SEM of quantitation
(fold change of control) of Ahr mRNA corrected for Gapdh mRNA as
internal standard in control and DMBA-induced adjacent mammary
tissues and tumors from 8 animals/group (n = 8). Different letters
represent statistical differences (P < 0.05)
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levels in rat [47] and human [53] mammary cells. Based
on this information, we compared Ccnd1 (cyclin D1)
and Cdk4 expression in control mammary gland, and ad-
jacent mammary tissues and tumors obtained from ani-
mals treated with DMBA (Fig. 5). We noticed that
compared to control, in DMBA-treated animals levels of
Cdk4 (Fig. 5a) and Ccnd1 (Fig. 5b) were increased re-
spectively an average ~3.0- and 1.0-fold in adjacent
mammary tissues; and an additional ~6.0- and 12.0-fold
increase was seen, respectively, for Cdk4 and Ccnd1, in
mammary tumors. Taken together, animal results sug-
gested that constitutive high Ahr expression and path-
way activation on the Cyp1b1 gene were linked to
induction of mammary tumorigenesis associated with re-
duced expression of BRCA-1 and ERα.
Targeting of AhR with αNF in human breast cancer cells
Increased expression and activation of the AhR may
contribute to epigenetic remodeling during early breast
carcinogenesis [54], whereas loss of BRCA-1 associates
with ERα-negativity in hereditary and sporadic breast tu-
mors [27]. Therefore, we compared the expression of
BRCA-1 and AhR in human ERα-positive MCF-7, and
ERα-negative UACC-3199 sporadic, breast cancer cells.
We selected these cell lines because MCF-7 cells express
wild-type BRCA-1 and are ERα-positive. Conversely,
UACC-3199 cells have wild-type but hypermethylated,
BRCA-1 [21, 55], and express low levels of ERα [56]. Re-
sults of Western blots informed that expression of
BRCA-1 was ~5.0-fold higher in MCF-7 compared to
UACC-3199 cells (Fig. 6a). Conversely, the expression of
the AhR was notably higher (~15.0-fold) in UACC-3199
compared to MCF-7 cells.
In previous studies with MCF-7 cells, we used αNF to
reverse the repressive effects of AhR agonists on BRCA-1
expression [38]. We then extended these studies to
UACC-3199 breast cancer cells. Results depicted in Fig. 6b
revealed that the treatment with αNF increased (~1.4-fold
of control) BRCA-1 mRNA; this change was associated
with a ~2.0-fold upregulation of BRCA-1 and ERα expres-
sion (Fig. 6c). Turning to other biological changes that oc-
curred in UACC-3199 cells along with reactivation of
BRCA-1 by αNF, we detected a large increase (~32-fold of
control) in CYP1A1 expression with only modest effects
(~1.5-fold increase compared to control) on CYP1B1
(Fig. 6d). Then, we compared the effects of αNF on
Fig. 4 Differential regulation of Cyp1a1 and Cyp1b1 in DMBA-induced
rat mammary adjacent tissues and tumors. Bars represent means ±
SEM of quantitation (fold change of control) of (a) Cyp1a1 and (b)
Cyp1b1 mRNA corrected for Gapdh mRNA as internal standard in
control and DMBA-induced adjacent mammary tissues and tumors
from 8 animals/group (n = 8). Different letters represent statistical
differences (P < 0.05)
Fig. 5 Expression of Cdk4 and Ccnd1 (cyclin D1) are increased in
DMBA-induced rat mammary adjacent tissues and tumors. Bars
represent means ± SEM of quantitation (fold change of control) of
(a) Cdk4 and (b) Ccnd1(cyclin D1) mRNA corrected for Gapdh
mRNA as internal standard in control and DMBA-induced adjacent
mammary tissues and tumors from 8 animals/group (n = 8). Different
letters represent statistical differences (P < 0.05)
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BRCA-1 and ERα expression in MCF-7 and UACC-3199
breast cancer cells. Results illustrated in Fig. 7 confirmed
that αNF increased ~2.0- and 3.0-fold of control respect-
ively, BRCA-1 and ERα in UACC-3199 cells, which were
however refractory to the treatment with E2 alone or in
combination with αNF. On the other hand, as previously
reported by our group [41, 42], the treatment of MCF-7
cells with αNF antagonized the E2-dependent induction of
BRCA-1. Overall, these cell culture studies implied that
the effects of αNF, selected as a prototype AhR antagonist,
were influenced by cell-context and ERα status, i.e. αNF
rescued BRCA-1 and ERα expression in sporadic and
ERα-negative UACC-3199 breast cancer cells carrying
hypermethylated BRCA-1. Conversely, αNF antagonized
E2-dependent stimulation of BRCA-1 expression in ERα-
positive MCF-7 breast cancer cells.
BRCA-1 promoter methylation and AhR expression in
human breast tumors
Next, we wished to explore if differential expression of
AhR and BRCA-1 promoter CpG methylation associated
Fig. 6 Rescue of BRCA-1 and ERα expression in sporadic UACC-3199 breast cancer cells with αNF. a Bands are representative baseline immunocomplexes
detected by Western blotting for BRCA-1 and AhR protein expression in MCF-7 and UACC-3199 breast cancer cells cultured respectively in control
phenol-red free DMEM or RPMI 1640 media supplemented with 10 % charcoal-stripped FCS; b UACC-3199 breast cancer cells were cultured in control
phenol-red free RPMI plus 10 % charcoal-stripped FCS in the absence (control) or presence of αNF (2 μM for 72 h). Bars represent means ± SEM of
quantitation of mRNA (fold change of control) performed twice in duplicate (n = 4) with four repeated measures/sample. BRCA-1 mRNA was
corrected for GAPDH mRNA as internal standard; c Bands are immunocomplexes detected by Western blotting for BRCA-1 and ERα in UACC-3199
breast cancer cells cultured in phenol-red free RPMI plus 10 % charcoal-stripped FCS in the absence (control) or presence of αNF (2 μM for 72 h).
GAPDH bands are internal standards for Western blotting; d Bars represent means ± SEM of quantitation of CYP1A1 and CYP1B1 mRNA (fold change of
control) performed twice in duplicate (n = 4) with four repeated measures/sample, and corrected for GAPDH mRNA as internal standard. In (b) and (d)
Asterisks represent statistical differences (P < 0.05) compared to control
Fig. 7 Differential effects of αNF on BRCA-1 and ERα expression in
MCF-7 and UACC-3199 breast cancer cells. Cells were cultured for
72 h in control phenol red-free media (DMEM for MCF-7; RPMI for
UACC-31299) supplemented with 10 % charcoal-stripped FCS in the
presence or absence of 10 nM E2, alone or in combination with
2 μM αNF. Bands are representative immunocomplexes detected by
Western blotting for BRCA-1, ERα, and GAPDH from two independent
experiments performed in duplicate (n = 4)
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with pathological classification of human breast tumor
subtypes based on receptor status. Therefore, we com-
pared the level of BRCA-1 promoter CpG methylation in
genomic DNA obtained from control breast tissue and
various breast tumor subtypes including TNBC, LUM-
A, HER-2-positive, and LUM-B. On average, we ob-
served that BRCA-1 promoter methylation (M/U ratio)
was increased ~6.6-fold in TBNC compared to non-
tumor breast tissue (Fig. 8). Conversely, compared to
non-tumor tissue, there were no differences in the
amount of BRCA-1 promoter methylation in LUM-A,
LUM-B, and HER-2-positive breast tumors. Interestingly,
the increased BRCA-1 promoter methylation in TNBC
correlated with increased expression (~3.0-fold of con-
trol) of AhR. Overall, these results denoted that coordi-
nated increase in AhR expression and BRCA-1 gene
hypermethylation may be molecular markers of TNBC.
Discussion
Earlier studies documented that the AhR is overex-
pressed and constitutively activate in rodent and human
mammary tumors [35]. These findings attributed to en-
vironmental and endogenous factors that activate the
AhR a role in breast tumorigenesis. Our prior cell cul-
ture [37–44] and rodent [47] model investigations of
breast cancer provided evidence that the BRCA-1 gene
was a molecular target for the AhR and various chroma-
tin remodeling factors. Specifically, the recruitment of
the activated AhR, DNMTs, and MBD-2 to the BRCA-1
gene culminated with placement of repressive histone
(H3K9me3) and DNA (CpG methylation) marks, and
downregulation of BRCA-1 expression.
The first objective of this study was to investigate the
association between AhR expression and/or activation
and Brca-1 promoter methylation status in mammary
tumors. For this purpose, we adopted the DMBA-rat
mammary tumor model based on the knowledge DMBA
is a strong AhR agonist [33] and mammary carcinogen
[48, 57]. The upregulation of Ahr and Cyp1b1 were par-
alleled by increased Brca-1 CpG methylation, and re-
duced expression of BRCA-1 and ERα in mammary
tumors induced with DMBA. Also, the reduction in
BRCA-1 expression observed in peritumoral tissue sug-
gested that Brca-1 CpG methylation may be an epigen-
etic event that occurs prior to overt mammary tumor
formation linked to Ahr overexpression and/or activa-
tion. This interpretation may have prognostic value since
adjacent non-tumor mammary tissue from DMBA-
treated animals had also increased expression of the pro-
liferation markers Cdk4 and Ccnd1 (cyclin D1). Overall,
results of animal experiments linked higher AhR expres-
sion and activity on the Cyp1b1 gene to increased risk of
mammary tumorigenesis [34, 48, 54, 57, 58] via epigen-
etic silencing of Brca-1.
The reduction in ERα expression observed in adjacent
mammary gland and mammary tumors of DMBA-
treated animals was consistent with previous reports of
reduced ERα in familial BRCA-1 tumors [25, 26], and
sporadic breast cancers with hypermethylated BRCA-1
[28]. The ERα and the BRCA-1 participate in a positive
feed-back loop whereby the ERα upregulates BRCA-1
[38], which in turn stimulates ERα expression [27].
Therefore, AhR-dependent repression of BRCA-1 via
increased CpG methylation may disrupt this positive
feedback loop between BRCA-1 and ERα and favor
the development of ERα- and BRCA-1-negative breast
tumors.
Turning to markers of AhR activation, we measured
increased Cyp1b1 in adjacent mammary gland and mam-
mary tumors of DMBA-treated animals. This accumulation
Fig. 8 Human TNBC harbor constitutive AhR expression and increased BRCA-1 promoter CpG methylation. Bars represent quantitation of BRCA-1
promoter CpG methylation (M/U ratio) and AhR expression in human TNBC (n = 4), LUM-A (n = 5), LUM-B (n = 4), and HER-2-positive (n = 5) breast
tumors. Asterisks represent statistical differences (P < 0.05) compared to non-tumor breast tissue control
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was consistent with previous studies reporting stimulation
of Cyp1b1 in rat models of mammary tumorigenesis [34,
48]. The CYP1B1 enzyme catalyzes the production from
E2 of mutagenic 4-hydroxy-E2 (4OH-E2) [59, 60]. It is
feasible that the constitutive activation of the AhR/CYP1B1
axis may have the synergistic effect of increasing DNA
damage via increased production of mutagenic 4OH-E2
while impairing DNA repair functions controlled by
BRCA-1. Conversely, we found that Cyp1a1 was reduced
in adjacent mammary gland and mammary tumors of
DMBA-treated animals. Consistent with these findings,
earlier studies documented preferential repression of
Cyp1a1 in DMBA-induced mammary tumors [48], as well
as in human invasive ductal carcinomas [61, 62] and breast
cancer cells lacking the ERα [50, 63]. Furthermore, reduced
CYP1A1 enzymatic activity has been linked to constitutive
activation of the AhR [64] and resistance of breast cancer
cells to apoptosis induced by DMBA [65].
To further elucidate the cross-talk between expression
and/or activation of AhR, and BRCA-1 regulation, we
turned to cell culture experiments using UACC-3199
sporadic breast cancer cells, which possess hypermethy-
lated BRCA-1 promoter [21, 55] and express low ERα
[56]. Compared to MCF-7 cells, UACC-3199 cells had
higher basal AhR, but lower BRCA-1. Therefore, we
tested whether or not treatment of UACC-3199 cells
with the AhR antagonist αNF rescued BRCA-1 expres-
sion. The rationale for this approach was based on our
previous studies showing that BRCA-1 silencing by AhR
agonists was reversed by cotreatment with α-NF [38].
The mechanisms of action of αNF as an AhR antagonist
and anticarcinogen have been related respectively, to re-
duction of transcriptionally active nuclear AhR com-
plexes [66, 67], and inhibition of 4OH-E2 production by
CYP1B1 [68]. The rescue of BRCA-1 and ERα by αNF in
UACC-3199 breast cancer cells were biological changes
associated with preferential induction of CYP1A1. Con-
versely, αNF did not affect ERα levels, but antagonized
E2-dependent activation of BRCA expression, in
ERα-positive MCF-7 cells. The latter findings were
in accord with our previous reports documenting re-
pression by αNF and 3-methoxy-4-naphthoflavone,
another antagonist of the AhR, of E2-dependent
transcriptional activation of the BRCA-1 gene [42].
These differential effects of αNF on BRCA-1 and
ERα expression could be attributed to interactions
between agonist/antagonist activities on the AhR and
ERα status [69]. This AhR-ERα cross-talk could be
exploited for the development of strategies aimed at
the reactivation of BRCA-1 and ERα in ERα-negative
and AhR-overexpressing tumors.
We further extended our studies of BRCA-1/AhR
cross-talk to human breast tumors, and found that com-
pared to LUM-A, LUM-B, and HER-2-positive tumors,
TNBC had higher AhR and BRCA-1 CpG methylation.
These observations provided additional support to the
hypothesis that constitutive AhR expression may be as-
sociated with hypermethylation of the BRCA-1 promoter
and the development of TNBC. It remains unknown
whether the reduced ERα expression in DMBA-induced
tumors, UACC-3199 cells, and TNBC tumors may be
due to hypermethylation, or disruption of expression of
transcription factors that regulate transcription, of the
ERα (ERS1) gene. Answering these queries may assist
with the development of strategies for coordinate epigen-
etic reactivation of BRCA-1 and ESR1 in ERα-negative
breast tissues.
Conclusions
Many studies have effectively utilized the AhR-agonist
and mammary carcinogen DMBA to examine the mo-
lecular pathways that contribute to breast cancer and ef-
ficacy of therapies [57]. To our knowledge, this is the
first study linking constitutive overexpression of the AhR
to BRCA-1 promoter hypermethylation in DMBA-
induced mammary tumors and human TNBC. The po-
tential prognostic significance of the current findings is
underscored by the fact the AhR is constitutively active
in ERα-negative human breast tumor cells [34, 35, 50,
61]. Ongoing studies in our laboratory are using in vitro
and vivo models to explore the effects of AhR knockout
on epigenetic regulation of BRCA-1 and ESR1 (ERα), and
the preventative effects of AhR antagonists. Progress in
these areas may help clarifying a causative role for the AhR
in breast tumorigenesis and assist with the development of
risk models for BRCA-1 mutation carriers [70, 71] and
sporadic TNBC, for which therapy options remains an in-
tensive area of investigation [72, 73].
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